Identification of potential therapeutic targets in prostate cancer through a cross‐species approach

  • Jurmeister S
  • Ramos‐Montoya A
  • Sandi C
  • et al.
6Citations
Citations of this article
42Readers
Mendeley users who have this article in their library.

Abstract

© 2018 The Authors. Published under the terms of the CC BY 4.0 license Genetically engineered mouse models of cancer can be used to filter genome-wide expression datasets generated from human tumours and to identify gene expression alterations that are functionally important to cancer development and progression. In this study, we have generated RNAseq data from tumours arising in two established mouse models of prostate cancer, PB-Cre/Pten loxP/loxP and p53 loxP/lox P Rb loxP/loxP , and integrated this with published human prostate cancer expression data to pinpoint cancer-associated gene expression changes that are conserved between the two species. To identify potential therapeutic targets, we then filtered this information for genes that are either known or predicted to be druggable. Using this approach, we revealed a functional role for the kinase MELK as a driver and potential therapeutic target in prostate cancer. We found that MELK expression was required for cell survival, affected the expression of genes associated with prostate cancer progression and was associated with biochemical recurrence.

Cite

CITATION STYLE

APA

Jurmeister, S., Ramos‐Montoya, A., Sandi, C., Pértega‐Gomes, N., Wadhwa, K., Lamb, A. D., … Neal, D. E. (2018). Identification of potential therapeutic targets in prostate cancer through a cross‐species approach. EMBO Molecular Medicine, 10(3). https://doi.org/10.15252/emmm.201708274

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free